Gitnux/Report 2026

Drug Discovery Industry Statistics

The global drug discovery market reached $124.11 billion in 2025, explore the figures behind growth, company scale, and AI-driven discovery trends.
13Statistics
23Sources
3Sections
1Visuals
13mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days

01 Industry overview

The drug discovery industry at a glance

The global drug discovery market reached $124.11 billion in 2025 and is forecast to expand rapidly as AI-enabled research, biologics, and rising pharmaceutical R&D investment reshape early-stage development.

$124.11B[8]
Global market size, 2025
15.1%[8]
Forecast CAGR, 2025–2030
55[9]
FDA novel drugs approved, 2026
$133B[10]
Biopharma M&A value, 2025
Market size
The global drug discovery market was valued at $124.11 billion in 2025, according to The Business Research Company. North America was the largest regional market in 2025.[8]
Forecast & CAGR
The market is projected to reach $250.51 billion by 2030, implying a 15.1% compound annual growth rate from 2025 to 2030.[8]
Market share & regions
North America held the largest regional position in 2025, while Asia-Pacific was identified as the fastest-growing region. The available source does not provide percentage shares for each region.[8]
Segmentation
Drug discovery is commonly segmented by process, drug type, technology, therapeutic area, and end user. The market source identifies small molecules and biologics as major drug-type categories and highlights oncology, infectious disease, and neurological disorders among the principal therapeutic areas.[8]
Trends, drivers & challenges
AI and digital technologies are increasingly being applied to target selection, candidate discovery, clinical planning, and R&D decision-making. The industry remains constrained by high development risk and the difficulty of converting early research into approved products; FDA approved 46 novel drugs in 2025, illustrating the limited annual output relative to the scale of discovery activity.[11][9]
M&A
Biopharma M&A value reached $133 billion in 2025, up 133% from 2024, while commercial-stage targets accounted for 49% of total value and Phase 3-focused transactions accounted for 28%. IQVIA also reported that M&A volume fell 7% to a five-year low, indicating fewer but larger transactions.[10]
Regulation
The FDA recorded 55 novel drug approvals in 2026 as of November 18, 2026, compared with 46 novel drugs approved by CDER during 2025. These figures cover novel drugs and therapeutic biologics reviewed by CDER, rather than every approval or label expansion.[9]
Latest news
The latest available 2026 FDA data listed 55 novel drug approvals by November 18, 2026. Industry dealmaking also remained a major source of pipeline access: IQVIA reported $133 billion in aggregate biopharma M&A value for 2025, driven by large strategic acquisitions.[9][10]

02 Ranking

Top 10 Companies in the Drug Discovery Industry

The leading companies in the drug discovery industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Eli Lilly stands out for medicines discovery and development because it reported $13.3 billion in 2025 R&D spending across discovery and development programs, while Roche is the pick for pharmaceutical and biologic drug discovery since it reported CHF47.7 billion in 2025 pharmaceutical sales.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in medicines discovery and development

    Eli Lilly

    US

    Ranked #1 · 9.8 · Medicines discovery and development

    Why we picked it: It funds discovery and development at $13.3 billion in 2025, with R&D at 20.5% of revenue.

  2. #2 overall

    Roche

    CH

    Ranked #2 · 9.3 · Medicines discovery and development

    Why we picked it: Its pharmaceutical and biologic discovery business sits behind CHF47.7 billion in 2025 pharma sales.

  3. #3 overall

    Novartis

    CH

    Ranked #3 · 9.2 · Medicines discovery and development

    Why we picked it: Innovative medicines net sales reached $54.5 billion in 2025, with R&D at 20.5% of revenue.

Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.

Full ranking

Sort by
Top 10 companies in the drug discovery industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly

Medicines discovery and development · US

9.8
2

Roche

Medicines discovery and development · CH

9.3
3

Novartis

Medicines discovery and development · CH

9.2
4

Novo Nordisk

Medicines discovery and development · DK

9.2
5

AstraZeneca

Medicines discovery and development · GB

9.2
6

Amgen

Biologic and peptide drug discovery · US

9.0
7

Johnson & Johnson

Pharmaceutical and biologic drug discovery · US

8.8
8

Sanofi

Global vaccine and medicines discovery · FR

8.7
9

Merck

Pharmaceutical and vaccine discovery · US

8.5
10

GSK

Vaccines and specialty medicines discovery · GB

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the drug discovery industry. In Drug Discovery Industry Statistics. Gitnux. https://gitnux.org/drug-discovery-industry-statistics/#top-companies

report visual · Comparison

Revenue of the largest drug discovery companies

Roche leads with $69.5B in annual revenue (group level, converted to USD).

Roche$69.5B
Eli Lilly$65.2B
AstraZeneca$58.7B
Novartis$54.5B
Novo Nordisk$44.8B
Amgen$36.8B
source-verifiedroche.com · investor.lilly.com · astrazeneca.com · novartis.com · sec.gov2025

04 Statistics

Market Intelligence

Drug discovery services scale is quantified with 2025 market values like $16.36 billion for chemistry and biology services. The same section provides long-horizon forecasts through 2035.

Market size and service revenue in the drug discovery industry

  • US$19.2 billion was the global drug discovery services market size in 2025, covering outsourced services across discovery activities, according to Global Market Insights.[1]
  • US$19.76 billion was the global drug discovery services market size in 2025, covering chemistry and biology services across discovery phases, drug types, therapeutic areas and end users.[2]
  • The global drug discovery services market was valued at US$14.89 billion in 2024 and US$16.36 billion in 2025, covering outsourced discovery services by process, type and geography.[3]

Growth forecasts for the drug discovery industry

  • The global drug discovery services market is projected to reach US$67.3 billion by 2035 from US$21.5 billion in 2026, implying a 13.5% CAGR during 2026–2035.[1]
  • The global drug discovery services market is projected to reach US$27.23 billion by 2030, growing at a 10.7% CAGR from 2025 to 2030.[3]
  • The global drug discovery services market is projected to reach US$36.22 billion by 2034 from US$21.11 billion in 2026, representing a 7.0% CAGR during 2026–2034.[2]

05 Statistics

Strategy & Growth

Deal activity is measured for biopharma-services M&A, including $8 billion in 2025 for the CRO, CDMO and life-sciences supplier segment. It also reports 272 deals completed in 2024.

M&A and consolidation in the drug discovery industry

  • $24.2 billion was the aggregate value of global biopharma-services M&A in 2024, compared with $20.5 billion in 2023; the scope includes CROs, CDMOs and related providers.[4]
  • 15 CRO, CDMO and supplier M&A transactions were recorded in 2025 in Deloitte’s life-sciences deal classification, a segment that includes providers serving drug discovery and development.[5]
  • $8 billion was the 2025 deal value for the global CRO, CDMO and life-sciences supplier segment, which includes drug-discovery service providers; Deloitte reported this was more than 70% below 2024.[5]
  • 272 biopharma-services M&A deals were completed globally in 2024, up from 267 in 2023; the scope includes CROs, CDMOs and related service providers, including discovery services.[4]

06 Statistics

Finance

Margins are benchmarked for major CROs, with a 30.0% estimated mean gross-profit margin in 2024. It also includes a 2024 operating margin figure for Charles River’s Discovery and Safety Assessment segment.

Margins and profitability in the drug discovery industry

  • 30.0% was the estimated mean gross-profit margin in 2024 for five major global CROs covered by the report, including Charles River, Fortrea, ICON, IQVIA and Medpace; the scope includes outsourced pharmaceutical services.[6]
  • 21.1% was the estimated mean EBITDA margin in 2024 for five major global CROs covered by the report, including Charles River, Fortrea, ICON, IQVIA and Medpace; the scope includes outsourced pharmaceutical services.[6]
  • 18.1% was Charles River Laboratories’ GAAP operating margin in 2024 for its Discovery and Safety Assessment segment, which combines drug discovery and safety-assessment services.[7]

Key questions about the drug discovery industry

How big is the global drug discovery market in 2025?
The global drug discovery market reached $124.11 billion in 2025.
What growth rate is expected for drug discovery through 2030?
The market is projected to reach $250.51 billion by 2030, implying a 15.1% CAGR from 2025 to 2030.
Which companies lead the drug discovery industry?
Eli Lilly stands out for medicines discovery and development because it reported $13.3 billion in 2025 R&D spending across discovery and development programs, while Roche is the pick for pharmaceutical and biologic drug discovery since it reported CHF47.7 billion in 2025 pharmaceutical sales.
Where is AI being used across drug discovery activities?
AI and digital technologies are increasingly applied to target selection, candidate discovery, clinical planning, and R&D decision-making.
How many novel drugs did the FDA approve in 2026 versus 2025?
The FDA recorded 55 novel drug approvals in 2026 as of November 18, 2026, compared with 46 novel drugs approved by CDER during 2025.
What does biopharma dealmaking look like in 2025?
Biopharma M&A value reached $133 billion in 2025, up 133% from 2024, while M&A volume fell 7% to a five-year low.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Drug Discovery Industry Statistics. Gitnux. https://gitnux.org/drug-discovery-industry-statistics
MLA
Samuel Norberg. "Drug Discovery Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/drug-discovery-industry-statistics.
Chicago
Samuel Norberg. 2026. "Drug Discovery Industry Statistics." Gitnux. https://gitnux.org/drug-discovery-industry-statistics.